E.E. Geduld’s Fate Therapeutics FATE Stock Holding History

E.E. Geduld’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-10,000	Closed	-$53K	–	202
2015 Q3	$53K	Sell	10,000 -27,000	-73%	-$184K	0.05%	152
2015 Q2	$239K	Buy	+37,000	New	+$221K	0.15%	157

Other funds holding FATE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

E.E. Geduld's FATE Position: Q4 2015 in Review

E.E. Geduld sold out of Fate Therapeutics (FATE) in Q4 2015, closing a stake of 10,000 shares — an estimated $53K sold.

E.E. Geduld first reported a position in FATE in Q2 2015 and held it in 2 quarters. The position peaked at $239K in Q2 2015. 54 funds tracked by Wall St. Rank hold FATE as of Q4 2015.

E.E. Geduld reported no remaining Fate Therapeutics position as of Q4 2015 after selling out during the quarter.
E.E. Geduld sold 10,000 Fate Therapeutics shares in Q4 2015, an estimated $53K.
E.E. Geduld first reported a position in Fate Therapeutics in Q2 2015 and held it in 2 quarters.
E.E. Geduld's Fate Therapeutics position peaked at $239K in Q2 2015.
54 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2015.

Based on E.E. Geduld's 13F filing for Q4 2015, filed 2 Feb 2016.